Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 47.14M | 45.56M | 12.76M | 95.91M | 0.00 | 0.00 |
Gross Profit | 47.14M | 45.56M | 12.76M | 95.91M | 0.00 | 0.00 |
EBITDA | -255.78M | -241.49M | -176.86M | -3.31M | -30.73M | -5.43M |
Net Income | -187.36M | -241.60M | -176.94M | -21.14M | -36.71M | -5.75M |
Balance Sheet | ||||||
Total Assets | 818.41M | 864.62M | 347.10M | 531.58M | 59.78M | 9.23M |
Cash, Cash Equivalents and Short-Term Investments | 808.48M | 834.19M | 340.45M | 438.52M | 53.09M | 7.86M |
Total Debt | 389.00K | 448.00K | 60.00K | 118.00K | 164.00K | 11.65M |
Total Liabilities | 41.05M | 107.12M | 58.70M | 47.06M | 9.99M | 12.81M |
Stockholders Equity | 777.36M | 757.50M | 288.39M | 484.52M | 49.79M | -3.58M |
Cash Flow | ||||||
Free Cash Flow | -86.55M | -159.24M | -141.24M | 7.96M | -25.18M | -5.98M |
Operating Cash Flow | -136.75M | -158.56M | -141.22M | 7.97M | -25.16M | -5.97M |
Investing Cash Flow | -59.40M | -62.85M | -24.00K | 715.00K | -20.00K | -13.00K |
Financing Cash Flow | 467.53M | 659.51M | 8.91M | 375.18M | 68.99M | 11.32M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | $1.84B | 12.05 | 24.71% | ― | 20.62% | 14.08% | |
65 Neutral | ¥345.58B | 10.59 | -2.88% | 2.65% | 11.80% | -6.84% | |
58 Neutral | $2.08B | ― | -31.51% | ― | ― | ― | |
56 Neutral | $2.04B | ― | -86.10% | ― | 29.32% | -11.00% | |
51 Neutral | $1.64B | ― | -70.58% | ― | 100.03% | 64.22% | |
45 Neutral | $2.05B | ― | -35.21% | ― | -100.00% | -144.79% | |
40 Underperform | $3.00B | ― | ― | ― | ― |
NewAmsterdam Pharma Company announced a Research & Development Day event scheduled for June 11, 2025, in New York City, aimed at analysts and investors. The event will be webcast live, with a replay available for 30 days. The company has been active in clinical trials, with significant developments in its BROOKLYN, BROADWAY, and TANDEM Phase 3 studies, and has secured funding to support a potential U.S. commercial launch. The company’s product candidate, Obicetrapib, shows promise in addressing cardiometabolic diseases, and there are ongoing efforts to explore its therapeutic potential in Alzheimer’s disease and multi-infarct dementia.
The most recent analyst rating on (NAMS) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on NewAmsterdam Pharma Company stock, see the NAMS Stock Forecast page.
On June 9, 2025, NewAmsterdam Pharma announced positive topline data from their Phase 3 BROADWAY clinical trial, which evaluated the effects of obicetrapib on Alzheimer’s Disease biomarkers. The study showed statistically significant reductions in the primary outcome measure of p-tau217 in both the full study population and ApoE4 carriers, suggesting a potential preventive strategy for Alzheimer’s Disease. These findings highlight the potential of CETP inhibition in mitigating Alzheimer’s risk and further differentiate obicetrapib as a uniquely effective therapy addressing multiple health concerns, including cardiovascular and neurodegenerative diseases.
The most recent analyst rating on (NAMS) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on NewAmsterdam Pharma Company stock, see the NAMS Stock Forecast page.
On June 4, 2025, NewAmsterdam Pharma Company N.V. held its annual general meeting where 74.45% of eligible shares voted. Shareholders approved several proposals, including the adoption of the 2024 annual accounts, discharge of directors’ liabilities, appointment of Deloitte as auditor, and various board appointments. The company also decided to hold annual Say-on-Pay votes until 2031.
The most recent analyst rating on (NAMS) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on NewAmsterdam Pharma Company stock, see the NAMS Stock Forecast page.
On May 7, 2025, NewAmsterdam Pharma announced additional data from its BROADWAY and TANDEM Phase 3 clinical trials, presented at the European Atherosclerosis Society Congress and published in leading medical journals. The data demonstrated significant reductions in LDL-C levels and improvements in cardiovascular biomarkers with the use of obicetrapib, both as monotherapy and in combination with ezetimibe, highlighting its potential as a foundational therapy in CVD management. The trials showed a 45% reduction in lipoprotein(a) and a 21% reduction in major adverse cardiovascular events, reinforcing obicetrapib’s promise as an effective oral treatment for CVD.
On April 15, 2025, NewAmsterdam Pharma appointed Adele Gulfo as an independent director to its Board of Directors, a strategic move as the company prepares for the potential launch of its drug obicetrapib next year. Gulfo’s extensive experience in pharmaceutical leadership and her history of successful drug launches are expected to significantly contribute to NewAmsterdam’s commercial strategy and infrastructure development, enhancing its position in the cardiovascular treatment market.